Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, August 1st. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.64) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The company had revenue of $108.83 million during the quarter, compared to analysts’ expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. Ultragenyx Pharmaceutical’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.33) EPS. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Ultragenyx Pharmaceutical Stock Down 1.2 %
RARE opened at $44.71 on Wednesday. The business’s fifty day simple moving average is $41.63 and its 200 day simple moving average is $44.44. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $54.56. The stock has a market cap of $3.72 billion, a PE ratio of -5.57 and a beta of 0.56.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on RARE
Insider Activity at Ultragenyx Pharmaceutical
In related news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the sale, the director now owns 7,248 shares in the company, valued at $297,892.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Karah Herdman Parschauer sold 9,806 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $441,270.00. Following the completion of the transaction, the executive vice president now owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the transaction, the director now owns 7,248 shares of the company’s stock, valued at approximately $297,892.80. The disclosure for this sale can be found here. Insiders sold a total of 12,127 shares of company stock worth $536,593 over the last quarter. 5.80% of the stock is owned by corporate insiders.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Recommended Stories
- Five stocks we like better than Ultragenyx Pharmaceutical
- Roth IRA Calculator: Calculate Your Potential Returns
- 5 Aggressive Growth Stocks for Long-Term Investors
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- Upcoming IPO Stock Lockup Period, Explained
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.